AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Worlddrugtracker, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his PhD from ICT ,1991, Mumbai, India, in Organic chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA as ADVISOR earlier GLENMARK LS Research centre as consultant,Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Prior to joining Glenmark, he worked with major multinationals like Hoechst Marion Roussel, now sSanofi, Searle India ltd, now Rpg lifesciences, etc. he is now helping millions, has million hits on google on all organic chemistry websites. His New Drug Approvals, Green Chemistry International, Eurekamoments in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 year tenure, good knowledge of IPM, GMP, Regulatory aspects, he has several international drug patents published worldwide . He gas good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, polymorphism etc He suffered a paralytic stroke in dec 2007 and is bound to a wheelchair, this seems to have injected feul in him to help chemists around the world, he is more active than before and is pushing boundaries, he has one lakh connections on all networking sites, He makes himself available to all, contact him on +91 9323115463, [email protected]

Isis Pharmaceuticals, Inc.announced that data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the American Society of Clinical Oncology in Chicago

 drugs  Comments Off on Isis Pharmaceuticals, Inc.announced that data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the American Society of Clinical Oncology in Chicago
Jun 042013
 

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the American Society of Clinical Oncology in Chicago. Results of the initial dose escalation study in patients with metastatic cancer showed that ISIS-STAT3Rx treatment resulted in partial responses that were durable and prolonged in two out of three patients with diffuse large B-cell lymphoma (DLBCL) who were refractory to prior chemotherapy treatments. Isis and AstraZeneca are currently evaluating ISIS-STAT3Rx, in two clinical studies in patients with advanced lymphoma and metastatic liver cancer.

Read more here:

http://www.heraldonline.com/2013/06/03/4913337/isis-pharmaceuticals-reports-encouraging.html

 

volleyball

by WORLD DRUG TRACKER

DR ANTHONY CRASTO

Share

Selumetinib is the first drug ever to show significant benefit for patients with advanced uveal melanoma

 Uncategorized  Comments Off on Selumetinib is the first drug ever to show significant benefit for patients with advanced uveal melanoma
Jun 042013
 

Two Array Invented MEK Inhibitors Showcased At ASCO
Sacramento Bee
AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer during the second half of 2013.

http://www.sacbee.com/2013/06/03/5466446/two-array-invented-mek-inhibitors.html

Two Array BioPharma-invented MEK inhibitors, selumetinib and MEK162, were showcased at the 49th annual meeting of the American Society of Clinical Oncology (ASCO).

 

by WORLD DRUG TRACKER

DR ANTHONY CRASTO

 

Share

Experimental Drug Shows Benefits Against Melanoma in Early Study, Lambrolizumab activates body’s immune system to kill cancerous cells, researchers say

 Uncategorized  Comments Off on Experimental Drug Shows Benefits Against Melanoma in Early Study, Lambrolizumab activates body’s immune system to kill cancerous cells, researchers say
Jun 032013
 

Experimental Drug Shows Benefits Against Melanoma in Early Study
U.S. News & World Report
SUNDAY, June 2 (HealthDay News) — A new drug called lambrolizumab appears to improve outcomes in patients with advanced melanoma, according to the results of a phase 1 trial. Lambrolizumab is an antibody that works by revealing the cancer to the immune system so it can mount a response and kill the cancer cells with few serious side effects, the researchers said.

read all at

http://health.usnews.com/health-news/news/articles/2013/06/02/experimental-drug-shows-benefits-against-melanoma-in-early-study

volleyball

by WORLD DRUG TRACKER

DR ANTHONY CRASTO

Share

Chinese researchers have developed the world’s first ever vaccine against a strain of enterovirus that can cause hand, foot and mouth disease,

 drugs  Comments Off on Chinese researchers have developed the world’s first ever vaccine against a strain of enterovirus that can cause hand, foot and mouth disease,
Jun 032013
 

World First Hand' Foot And Mouth Vaccine Developed

AsianScientist (Jun. 3, 2013) – By Sunanda Creagh – Chinese researchers have developed the world’s first ever vaccine against a strain of enterovirus that can cause hand, foot and mouth disease, a condition commonly affecting small children that can lead to deadly infection of the brain and spinal cord membranes.

read all at

http://www.asianscientist.com/health-medicine/world-hand-foot-mouth-vaccine-developed-2013/

Share

GSK, Genmab announce positive results from Phase III study of Arzerra (ofatumumab)

 drugs  Comments Off on GSK, Genmab announce positive results from Phase III study of Arzerra (ofatumumab)
Jun 012013
 

may30,2013–GlaxoSmithKline (GSK) and Genmab (GEN) have announced positive results from Phase III study of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of chronic lymphocytic leukaemia (CLL) patients.

Share

Discovery of Unexpectedly Active Group-Introduction of a sulfoximine group into anticancer candidates shows that sometimes sticking to the unconventional pays off

 Uncategorized  Comments Off on Discovery of Unexpectedly Active Group-Introduction of a sulfoximine group into anticancer candidates shows that sometimes sticking to the unconventional pays off
May 312013
 

thumbnail image: Discovery of Unexpectedly Active Group

Introduction of a sulfoximine group into anticancer candidates shows that sometimes sticking to the unconventional pays off

Read more

Share

A Drug Discovery Detective Story-Biological activity of small-molecule RNA polymerase (RNAP) inhibitors revealed to come from polymeric impurity

 Uncategorized  Comments Off on A Drug Discovery Detective Story-Biological activity of small-molecule RNA polymerase (RNAP) inhibitors revealed to come from polymeric impurity
May 312013
 

thumbnail image: A Drug Discovery Detective Story

Biological activity of small-molecule RNA polymerase (RNAP) inhibitors revealed to come from polymeric impurity

Read more

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: